# Impact of Perioperative Dexamethasone Administration on Infection and Implant Osseointegration in a Preclinical Model of Orthopedic Device-Related Infection

**Authors:** Marc-Antoine Burch, Aron Keshishian, Charlotte Wittmann, Dirk Nehrbass, Keith Thompson, Daniel Arens, R. Geoff Richards, Vuysa Mdingi, Marco Chitto, Mario Morgenstern, T. Fintan Moriarty, Henk Eijer

PMC · DOI: 10.3390/microorganisms12061134 · Microorganisms · 2024-06-01

## TL;DR

This study examines how dexamethasone affects infection and bone integration around orthopedic implants in rats.

## Contribution

The study provides new insights into the effects of dexamethasone on infection and bone formation in orthopedic device-related infections.

## Key findings

- Dexamethasone did not increase the risk of infection or periprosthetic osteolysis.
- Long-term dexamethasone treatment increased new bone formation around implants.
- Low osseointegration was observed despite increased bone formation.

## Abstract

Glucocorticoids may be given prior to major orthopedic surgery to decrease postoperative nausea, vomiting, and pain. Additionally, many orthopedic patients may be on chronic glucocorticoid therapy. The aim of our study was to investigate whether glucocorticoid administration influences Orthopedic-Device-Related Infection (ODRI) in a rat model. Screws colonized with Staphylococcus epidermidis were implanted in the tibia of skeletally mature female Wistar rats. The treated groups received either a single shot of dexamethasone in a short-term risk study, or a daily dose of dexamethasone in a longer-term interference study. In both phases, bone changes in the vicinity of the implant were monitored with microCT. There were no statistically significant differences in bacteriological outcome with or without dexamethasone. In the interference study, new bone formation was statistically higher in the dexamethasone-treated group (p = 0.0005) as revealed by CT and histopathological analysis, although with relatively low direct osseointegration of the implant. In conclusion, dexamethasone does not increase the risk of developing periprosthetic osteolysis or infection in a pre-clinical model of ODRI. Long-term administration of dexamethasone seemed to offer a benefit in terms of new bone formation around the implant, but with low osseointegration.

## Linked entities

- **Chemicals:** dexamethasone (PubChem CID 5743)

## Full-text entities

- **Diseases:** pain (MESH:D010146), periprosthetic osteolysis (MESH:D057068), Infection (MESH:D007239), ODRI (MESH:D009140), postoperative nausea, vomiting (MESH:D020250)
- **Chemicals:** Dexamethasone (MESH:D003907)
- **Species:** Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116], Staphylococcus epidermidis (species) [taxon 1282]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11205448/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11205448/full.md

## References

37 references — full list in the complete paper: https://tomesphere.com/paper/PMC11205448/full.md

---
Source: https://tomesphere.com/paper/PMC11205448